Neuraxis INC
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
NRXS$6.25-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
** Balance Sheets**
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $78,560 | $253,699 |
| Accounts receivable, net | 73,167 | 174,399 |
| Inventories | 21,220 | 48,133 |
| Prepaids and other current assets | 69,663 | 726 |
| Total current assets | 242,610 | 476,957 |
| Property and Equipment, at cost: | 436,626 | 405,845 |
| Less - accumulated depreciation | (348,074) | (317,834) |
| Property and equipment, net | 88,552 | 88,011 |
| Other Assets: | ||
| Deferred offering costs | — | 736,736 |
| Operating lease right of use asset, net | 70,263 | 101,382 |
| Intangible assets, net | 108,073 | 77,558 |
| Total Assets | $509,498 | $1,480,644 |
** Balance Sheets**
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Liabilities | ||
| Current Liabilities: | ||
| Accounts payable | $1,204,219 | $1,592,116 |
| Accrued expenses | 401,088 | 834,062 |
| Notes payable | 148,062 | 202,834 |
| Current portion of operating lease payable | 49,127 | 33,395 |
| Notes payable - related party | — | 58,051 |
| Notes payable - convertible notes, net of unamortized discount of $0 and $3,327,213 as of December 31, 2023 and December 31, 2022 | — | 228,342 |
| Customer deposits | 74,947 | 59,174 |
| Derivative liabilities | — | 1,735,700 |
| Warrant liabilities | 8,225 | 2,234,384 |
| Total current liabilities | 1,885,668 | 6,978,058 |
| Non-current Liabilities: | ||
| Operating lease payable, net of current portion | 27,071 | 76,199 |
| Total non-current liabilities | 27,071 | 76,199 |
| Total liabilities | 1,912,739 | 7,054,257 |
| Commitments and contingencies (see note 14) | ||
| Stockholders’ Deficit | ||
| Convertible Series A Preferred stock, $0.001 par value; 1,000,000 shares authorized; 0 issued and outstanding as of December 31, 2023 and 506,637 as of December 31, 2022 | — | 507 |
| Convertible Series Seed Preferred Stock, $0.001 par value; 120,000 shares authorized; 0 issued and outstanding as of December 31, 2023 and 115,477 as of December 31, 2022 | — | 115 |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 6,508,897 issued and outstanding as of December 31, 2023 and 1,963,322 as of December 31, 2022 | 6,509 | 1,963 |
| Additional paid in capital | 47,148,361 | 28,355,230 |
| Accumulated deficit | (48,558,111) | (33,931,428) |
| Total stockholders’ deficit | (1,403,241) | (5,573,613) |
| Total Liabilities and Stockholders’ Deficit | $509,498 | $1,480,644 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.